PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 美國的醫藥品市場到2023年前的預測與市場分析
PharmaPoint: Macular Edema and Macular Degeneration - US Drug Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 219 Pages
|PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 美國的醫藥品市場到2023年前的預測與市場分析 PharmaPoint: Macular Edema and Macular Degeneration - US Drug Forecast and Market Analysis to 2023|
|出版日期: 2014年10月31日||內容資訊: 英文 219 Pages||
本報告提供美國的黃斑部水腫 (ME) 和黃斑部病變 (MD) 的治療藥市場相關調查分析，提供您疾病的概要與指南，競爭情形，主要藥物的詳細資訊 (產品說明，安全性，有效性) 、SWOT分析，銷售額預測，影響分析 (趨勢，推動因素·阻礙因素) 等相關的系統性資訊。
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
The corticosteroid implants Ozurdex and Iluvien are also anticipated to enter the US DME market during the forecast period, with Ozurdex receiving FDA approval as a DME treatment in June 2014, and Iluvien expected to launch in Q1 2015 following it's approval in September 2014. This new class of drugs is expected to be a significant driver of growth in the overall ME market, and by the end of the forecast period in 2023.